Solid Biosciences (SLDB) Restructuring Costs (2020 - 2023)
Quarterly results put Restructuring Costs at -$63000.0 for Q2 2023, down 104.14% from a year ago — trailing twelve months through Dec 2023 was $5.6 million (down 22.05% YoY), and the annual figure for FY2023 was -$63000.0, down 100.88%.
Solid Biosciences has reported Restructuring Costs over the past 3 years, most recently at -$63000.0 for Q2 2023.
- Restructuring Costs reached -$63000.0 in Q2 2023 per SLDB's latest filing, down from $5.7 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $5.7 million in Q4 2022 and bottomed at -$63000.0 in Q2 2023.
- Median Restructuring Costs over the past 3 years was $1.7 million (2020), compared with a mean of $2.3 million.
- Peak annual rise in Restructuring Costs hit 104.14% in 2023, while the deepest fall reached 104.14% in 2023.
- Over 3 years, Restructuring Costs stood at $1.9 million in 2020, then skyrocketed by 191.05% to $5.7 million in 2022, then crashed by 101.11% to -$63000.0 in 2023.
- Business Quant data shows Restructuring Costs for SLDB at -$63000.0 in Q2 2023, $5.7 million in Q4 2022, and $1.5 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -63,000.00 |
| Dec 31, 2022 | 5.66 Mn |
| Jun 30, 2022 | 1.52 Mn |
| Mar 31, 2020 | 1.94 Mn |